Cargando…
Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report
A patient with severe asthma on benralizumab therapy was admitted to the intensive care unit (ICU) for a coronavirus disease 2019 (COVID-19) infection. At the end of the 8 week benralizumab dosing interval, discussion arose as to whether benralizumab should be administered or if treatment should be...
Autores principales: | Kroes, Johannes Anthon, Zielhuis, Sander Wilhelm, Bethlehem, Carina, Ten Brinke, Anneke, Van Roon, Eric Nico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251165/ https://www.ncbi.nlm.nih.gov/pubmed/33883206 http://dx.doi.org/10.1136/ejhpharm-2020-002660 |
Ejemplares similares
-
Clinical response to benralizumab can be predicted by combining clinical outcomes at 3 months with baseline characteristics
por: Kroes, Johannes A., et al.
Publicado: (2023) -
Cumulative corticosteroid-sparing effect of anti-interleukin-5/5Ra in eosinophilic asthma
por: Kroes, Johannes A., et al.
Publicado: (2022) -
Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia
por: Isomoto, Kohsuke, et al.
Publicado: (2020) -
The clinical profile of benralizumab in the management of severe
eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016) -
Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab
por: Just, Jocelyne, et al.
Publicado: (2020)